title: Lifespan analysis of 212 transplanted kidney grafts: effects of use of humanized anti-IL-2R monoclonal antibody in graft survival at 1, 3, and 5 years for 108 recipients.
abstract: BACKGROUND
  The use of new drugs and new immunosuppressant schemes, as well as induction therapy with anti-IL-2R monoclonal antibody has significantly contributed to prolonged renal graft survival, especially in cadaveric grafts. However, what has led to this improvement has not been defined yet.
  
  
  OBJECTIVE
  Analyze the outcome of induction of humanized anti-IL-2R monoclonal antibodies on 1, 3 and 5 year survivals of 212 renal transplants from 1999 to 2005.
  
  
  METHODS
  We analyzed the lifespan of grafts using Kaplan-Meier curves, using a significance level of alpha = 0,05 for 212 renal allografts.
  
  
  RESULTS
  The global result for 1, 3 and 5 year survival curves of patients who received the induction therapy was 88%, 86% and 86%, and for recipients who did not receive induction was 81%, 81% and 81%, respectively. Likewise, cadaveric donors who received induction displayed 88%, 88% and 88%, and those who did not receive it 62%, 62% and 62% (p = 0,0089).
  
  
  CONCLUSIONS
  Despite the time and the number of transplants using induction therapy being modest, at 1, 3 and 5 years there was an increased lifespan, especially for cadaveric grafts, among patients who received induction, with IL2Ra antibodies.
authors.affiliation: Central de Transplantes do Agreste, Casa de Saude Santa Efigênia, Caruaru, Pernambuco, CEP 55014-250 Brazil. rfmaciel@uol.com.br
authors.forename: R F
authors.initials: RF
authors.lastname: Maciel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002102:Cadaver; D005260:Female; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008017:Life Expectancy; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2